Wrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis

ConditionRhematoid Arthritis

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age16-60

SponsorSohag University

About this trial

Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues.\[1\]

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

RA patients fulfilled the 2010 American College of Rheumatoid Arthritis classification criteria.[8]

Oligoarticular RA patients including wrist joint.

Age above 18 years old.

Patient cooperative and can answer questions.

Disqualifiers

Other rheumatologic or collagen diseases.

Age below 18 years.

Patients who underwent concomitant procedures to address underlying pathology such as radial styloidectomy, ulna shortening, fracture fixation, arthroplasty, arthrodesis, and ligament reconstructions.

Patients who suffered from hand deformities or limitation.

Trial design

Design model

Parallel

Treatments tested in this trial

Wrist local steroid injection
Procedure/Surgery
Wrist nerve block by injection is a diagnostic or therapeutic procedure used to treat chronic wrist pain, typically arising from arthritis or instability, by interrupting sensory nerve signals (mainly PIN/AIN nerves) with an anesthetic or neurolytic agent. This less-invasive approach provides pain relief, often serving as a predictor for success before permanent surgical denervation.\[4\]

Treatment groups

180 Participants

are divided into 3 treatment groups

Group A: Group 1Active comparator 1 intervention

Group B: Group 2Placebo comparator 1 intervention

Group C: Group 3No intervention 0 interventions

Trial outcomes

Primary outcomes

Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16

Change in wrist pain severity measured using the Visual Analogue Scale (VAS) from baseline to Week 16 Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Wrist pain severity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate greater pain. The change in VAS score from baseline to Week 16 will be assessed.

Time frame

Baseline to Week 16

Assessment of wrist pain improvement

• Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16

Time frame

16 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: